Sharemaestro Newsreel

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Solventum Corp. stock rises Friday, outperforms market

Solventum Corp. (SOLV) stock increased by 2.46% to $88.59 on Friday, marking its third consecutive day of gains. This rise occurred during a generally negative trading session where the S&P 500 Index (SPX) fell 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%, …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 2,192,980 shares of Elutia Inc. (ELUT) Class A common stock, representing a 4.9% stake. This disclosure, made via an amended Schedule 13G filing, indicates shared voting and dispositive power over these …

Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High‑Risk COVID Market

Pfizer Inc. has completed a real-world study in Korea on Paxlovid, demonstrating its effectiveness in older adults within long-term care hospitals against severe COVID-19, mortality, and decline in daily function. This observational study, which compared Paxlovid users to non-users matched on various factors, supports …

Viatris Inc. stock rises Friday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.18% to $16.23 on Friday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain ended a two-day losing streak for Viatris, indicating a resilient performance against broader …

Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics?

Steris PLC stock outperforms competitors despite losses on the day

Steris PLC stock (STE) fell 1.18% to $233.28 on Friday, marking its fourth consecutive day of losses. Despite this, the stock outperformed the broader market, as the S&P 500 Index (SPX) dropped 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%.

Labcorp Holdings Inc. stock outperforms competitors despite losses on the day

Shares of Labcorp Holdings Inc. (LH) experienced a 1.38% drop on Friday, closing at $318.13. Despite this loss and an overall poor trading day for the stock market, with the S&P 500 and Dow Jones also falling, Labcorp's stock still outperformed its competitors. This …

DYAI: Second Quarter Results

DexCom Inc. stock underperforms Friday when compared to competitors

Shares of DexCom Inc. (DXCM) fell by 1.89% to $89.75 on Friday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. This drop ended a six-day winning streak for the company's stock.

Innate Pharma increases equity bookbuild by a third to €30m

Innate Pharma has increased its equity bookbuild by one-third to €30 million, driven by a new $75 million partnership to develop a lymphoma treatment. The article indicates that this partnership was a significant "catalyst for investors." The full details are available to subscribers of …

Mereo BioPharma (MREO): EcoR1 reports 0.6% passive stake via ADS holdings

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported a passive beneficial ownership of 0.6% each in Mereo BioPharma Group plc. This stake, held through American Depositary Shares (ADS), represents 5,000,000 Ordinary Shares for EcoR1 and Nodelman, and 4,732,750 Ordinary …

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

IM Cannabis reports Q2 results

IM Cannabis press release [https://seekingalpha.com/filing/309949813] (IMCC [https://seekingalpha.com/symbol/IMCC]): Q2 revenue of $7.6 million, compared to $12.7 million in the same period in 2025. * Gross profit of $1.5 million, compared to $3.4 million in the same period in 2025. * Operating loss of $2.1 million, …

Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031

Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level,” said (President, CEO …

NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake

Squadron Master Fund LP and its related parties, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have disclosed a 1.6% equity stake in NextCure, Inc. through a SCHEDULE 13G/A SEC filing. This group beneficially owns 64,464 shares of NextCure common stock and …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …

Satellos Bioscience Inc. GAAP EPS of -$0.56

* Satellos Bioscience Inc. press release [https://seekingalpha.com/filing/309950026] (MSCL:CA [https://seekingalpha.com/symbol/MSCL:CA]): Q2 GAAP EPS of -$0.56. * Research and development expenses increased by $5,200 to $9,635 for the three months ended June 30, 2026, compared to $4,435 for the three months ended June 30, 2025, and …

Cigna Group stock outperforms competitors on strong trading day

Cigna Group (CI) shares rose 1.64% to $282.56, outperforming the broader market on a day when the S&P 500 and Dow Jones Industrial Average both fell. This marks the third consecutive day of gains for Cigna Group's stock.

LifeStance Health Group (NASDAQ:LFST) Given New $13.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has raised its price target for LifeStance Health Group (NASDAQ:LFST) to $13.00 from $9.00, while maintaining a "neutral" rating. This new target implies a potential upside of 2.48% from the stock's previous close. The company recently reported strong quarterly earnings, …

LifeStance Health Group (LFST) Turned Profitable And Lifted Guidance, Is It Still Below Fair Value?

Cooper Creek’s 9.6% WW International (WW) stake detailed in Schedule 13G/A

Cooper Creek Partners Management LLC has reported a passive beneficial ownership of 9.6% in WW International, Inc. (WW), amounting to 961,719 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares and certifies that the stake is …

HTFL Stock Rockets On Heavy Volume As Traders Pile In

Heartflow, Inc. (HTFL) stock surged over 30% due to optimism surrounding its AI-driven cardiovascular imaging breakthrough. The company, despite running deep losses, boasts strong gross margins, a robust cash position, and low debt, making it attractive for momentum traders despite its speculative growth profile. …

Teladoc Health (TDOC) Could Be 55% Undervalued On Board Change And 2026 Guidance

Teladoc Health (TDOC) is considered 55% undervalued by Simply Wall St, with a fair value of $15.00 against its current price of $6.81. This assessment follows the appointment of Mark V. Anquillare to its board and updated 2026 guidance, highlighting the company's cash generation, …

Dianthus Therapeutics stock hits 52-week high at 114.64 USD

Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $114.64, trading at $114.68, marking a 441% increase over the past year and 166% year-to-date. This surge follows recent positive developments, including the announcement of second-quarter 2026 earnings, the introduction of a …

Palatin Technologies (PTN) gains 4.7% stake holder AuGC BioFund in 13G/A

AuGC BioFund LP, along with AuGC Partners LLC and Evan Markegard, has reported a beneficial ownership of 84,000 shares of Palatin Technologies Inc. common stock, representing 4.7% of the total outstanding class. This ownership confers shared voting and dispositive power over the shares. The …

StemPoint Capital reports 5.0% Surrozen (SRZN) stake via shares and warrants

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have collectively reported a beneficial ownership of 5.0% in Surrozen, Inc. (SRZN). This stake includes 273,140 shares of common stock and 329,658 shares issuable upon exercise of Series A, B, and E warrants, …

Why Alphatec Holdings (ATEC) Is Up 5.9% After Reaffirming 2026 Outlook And Narrowing Q2 Losses

Alphatec Holdings (ATEC) saw its stock rise by 5.9% after announcing Q2 results that showed a narrowed net loss and reaffirmed its 2026 revenue guidance of approximately US$882 million. The company also filed an US$8.12 million shelf registration related to an ESOP offering. This …

TELA BIO (TELA): SilverArc Capital and Devesh Gandhi disclose 2.14M-share 4.8% stake

SilverArc Capital Management, LLC and Devesh Gandhi have filed an amended Schedule 13G, disclosing a beneficial ownership of 2,137,201 shares of TELA Bio, Inc. Class A Common Stock, representing 4.8% of the class. The filing indicates they hold shared voting and dispositive power over …

Deadline Alert: Insulet Corporation (PODD) Shareholders Who

Glancy Prongay Wolke & Rotter LLP is urging Insulet Corporation (NASDAQ: PODD) shareholders who lost money to contact them regarding a securities fraud lawsuit. The class action alleges Insulet made misleading statements and failed to disclose defective manufacturing controls, leading to product recalls and …

Innovative Eyewear (LUCY) grows revenue 74% but stays unprofitable in Q2 2026

Innovative Eyewear, Inc. (LUCY) reported a 74% increase in revenue for Q2 2026, reaching $1,010,519, primarily driven by strong sales of Lucyd Armor smart safety glasses and Reebok-branded smartglasses. Despite the significant revenue growth and improved gross margin of 24%, the company continued to …

Innovative Eyewear Reports 74% Revenue Growth in Q2

Innovative Eyewear reported a significant 74% year-over-year revenue growth in Q2 2026, reaching over $1 million for the first time. The company also improved its gross margin to 24% and reduced operating expenses, demonstrating effective cost management. With strategic initiatives and partnerships, Innovative Eyewear …

Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path

(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …

Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding